Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVIR NASDAQ:CCXI NASDAQ:HCM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVIRAtea Pharmaceuticals$4.87+1.9%$4.53$2.78▼$6.45$382.13M0.31350,193 shs159,886 shsCCXIChurchill Capital Corp XI$14.83+3.1%$12.40$10.07▼$19.69$1.06B1.221.14 million shs2.15 million shsHCMHUTCHMED$11.18-1.2%$11.18$9.77▼$19.50$1.97B0.2450,868 shs33,252 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVIRAtea Pharmaceuticals+1.88%+3.62%+11.70%-13.19%+41.98%CCXIChurchill Capital Corp XI+3.06%-7.14%+43.08%+43.58%+1,482,999,900.00%HCMHUTCHMED-1.24%-0.62%+8.75%-23.21%-36.98%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVIRAtea Pharmaceuticals$4.87+1.9%$4.53$2.78▼$6.45$382.13M0.31350,193 shs159,886 shsCCXIChurchill Capital Corp XI$14.83+3.1%$12.40$10.07▼$19.69$1.06B1.221.14 million shs2.15 million shsHCMHUTCHMED$11.18-1.2%$11.18$9.77▼$19.50$1.97B0.2450,868 shs33,252 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVIRAtea Pharmaceuticals+1.88%+3.62%+11.70%-13.19%+41.98%CCXIChurchill Capital Corp XI+3.06%-7.14%+43.08%+43.58%+1,482,999,900.00%HCMHUTCHMED-1.24%-0.62%+8.75%-23.21%-36.98%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVIRAtea Pharmaceuticals 2.50Moderate BuyN/AN/ACCXIChurchill Capital Corp XI 1.00SellN/AN/AHCMHUTCHMED 2.40Hold$15.3036.85% UpsideCurrent Analyst Ratings BreakdownLatest CCXI, AVIR, and HCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026AVIRAtea Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026HCMHUTCHMED Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)7/7/2026HCMHUTCHMED Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $17.006/29/2026HCMHUTCHMED Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/28/2026HCMHUTCHMED Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$13.605/6/2026CCXIChurchill Capital Corp XI Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell (E)5/1/2026HCMHUTCHMED Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)(Data available from 7/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVIRAtea PharmaceuticalsN/AN/AN/AN/A$3.53 per shareN/ACCXIChurchill Capital Corp XI$37.20M28.45N/AN/AN/A∞HCMHUTCHMED$548.51M3.56$2.66 per share4.20$7.17 per share1.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVIRAtea Pharmaceuticals-$158.35M-$2.11N/AN/AN/AN/A-57.01%-51.49%8/6/2026 (Estimated)CCXIChurchill Capital Corp XIN/A-$1.89N/AN/AN/AN/AN/AN/AN/AHCMHUTCHMED$456.91MN/AN/A39.93N/AN/AN/AN/A7/30/2026 (Estimated)Latest CCXI, AVIR, and HCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026AVIRAtea Pharmaceuticals-$0.56N/AN/AN/A$33.03 millionN/A7/30/2026H1 2026HCMHUTCHMED$0.15N/AN/AN/A$306.40 millionN/A5/12/2026Q1 2026AVIRAtea Pharmaceuticals-$0.60-$0.57+$0.03-$0.57$22.42 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVIRAtea PharmaceuticalsN/AN/AN/AN/AN/ACCXIChurchill Capital Corp XIN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVIRAtea PharmaceuticalsN/A7.897.89CCXIChurchill Capital Corp XIN/AN/AN/AHCMHUTCHMED0.054.964.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVIRAtea Pharmaceuticals86.67%CCXIChurchill Capital Corp XI81.09%HCMHUTCHMED8.82%Insider OwnershipCompanyInsider OwnershipAVIRAtea Pharmaceuticals21.60%CCXIChurchill Capital Corp XI8.30%HCMHUTCHMED3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVIRAtea Pharmaceuticals7080.03 million62.74 millionOptionableCCXIChurchill Capital Corp XIN/A71.36 millionN/AN/AHCMHUTCHMED1,796174.47 million168.19 millionNot OptionableCCXI, AVIR, and HCM HeadlinesRecent News About These CompaniesHutchmed: Bullish On Their Commercial Prospects And Pipeline CatalystsJuly 19 at 9:00 AM | seekingalpha.comHUTCHMED (NASDAQ:HCM) Stock Price Down 6% - Here's WhyJuly 17, 2026 | marketbeat.comHUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET AmplificationJuly 2, 2026 | globenewswire.comHUTCHMED to Announce 2026 Half-Year Financial ResultsJune 30, 2026 | globenewswire.comHUTCHMED's experimental drug shows durable responses in advanced bile duct cancer trialJune 25, 2026 | msn.comSyndio Acquires Embrace.aiJune 23, 2026 | businesswire.comisolved Introduces Autonomous AI Agents Built to Own HR Outcomes — Brings Unified HCM Platform to Anthropic's Claude Connectors DirectoryJune 16, 2026 | globenewswire.comEdgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)June 16, 2026 | prnewswire.comisolved Honors Top-Performing Partners at Annual Connect for Partners EventJune 15, 2026 | globenewswire.comisolved Introduces New Strategic Marketplace Partners at Connect 2026, Extending People Cloud™ Capabilities for Employers and EmployeesJune 15, 2026 | globenewswire.comPaychex Recognized as a Top WorkTech Company by TIMEJune 15, 2026 | globenewswire.comHUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 CongressJune 11, 2026 | globenewswire.comHUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual MeetingMay 21, 2026 | globenewswire.comInnovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally ...May 21, 2026 | uk.finance.yahoo.comHUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally ...May 21, 2026 | markets.businessinsider.comHUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell CarcinomaMay 21, 2026 | globenewswire.comAward-winning HR Software Vendor HiBob Named an ISG 2026 Vendor of Excellence for Human Capital Management (HCM) SuitesMay 20, 2026 | globenewswire.comAward-winning HR Software Vendor HiBob Named an ISG 2026 Vendor of Excellence for Human Capital Management (HCM) PlatformsMay 18, 2026 | globenewswire.comChengdu Origen and Vanotech Announce KHN921 Investigational New Drug application clearance by the US FDA for the treatment of hypertrophic cardiomyopathy (HCM) associated with MYBPC3 mutationsMay 13, 2026 | globenewswire.comHutchmed progresses China NDA for sovleplenibApril 29, 2026 | thepharmaletter.comTHUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaApril 29, 2026 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026Micron’s Sudden Plunge May Be an AI Buying ChanceBy Jeffrey Neal Johnson | June 23, 2026Agility Robotics’ SPAC Deal Opens a Rare Door Into Humanoid AIBy Jeffrey Neal Johnson | July 2, 2026Grounded: SpaceX Stumbles as Grok Fails to IgniteBy Jeffrey Neal Johnson | July 9, 2026CCXI, AVIR, and HCM Company DescriptionsAtea Pharmaceuticals NASDAQ:AVIR$4.87 +0.09 (+1.88%) Closing price 07/21/2026 04:00 PM EasternExtended Trading$4.86 0.00 (-0.10%) As of 07/21/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.Churchill Capital Corp XI NASDAQ:CCXI$14.83 +0.44 (+3.06%) Closing price 07/21/2026 04:00 PM EasternExtended Trading$14.75 -0.08 (-0.55%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Churchill Capital Corp XI is a blank check company.HUTCHMED NASDAQ:HCM$11.18 -0.14 (-1.24%) Closing price 07/21/2026 04:00 PM EasternExtended Trading$11.17 -0.01 (-0.09%) As of 07/21/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3M's Redemption Arc: Can Q2 Earnings Change the Narrative? Alphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of Earnings 3 Photonics Companies Making Quantum Tech Possible Confidence Is Back, But Earnings Show the Consumer Is Being Picky Industrial and Utility Giants Boost Dividends as Data Center Tailwinds Build IREN’s $2.8 Billion AI Contract Haul Changes the Stock’s Story AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 2 ETFs to Access the World's Best-Performing Stock Markets In 2026 Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
